Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
XKEM
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by dollar13: [QB] Industry Conference 10th Annual Biotech/Specialty Pharma Conference DATE December 12–13, 2006 TIME Day One 8:30 a.m.–4:30 p.m. Day Two 8:30 a.m.–4:30 p.m. CHAIRS Sherry Lombardi, The Answer Factory Laurie Malen, The Answer Factory LOCATION NYSSA 1177 Avenue of the Americas, 2nd Floor (between 45th and 46th Streets), NYC (Directions) Photo ID required for access to the building. REGISTER/FEE Early Registration by November 28 One Day: Members $195 | Nonmembers $295 Two Days: Members $295 | Nonmembers $395 Registration November 29 to December 5 One Day: Members $265 | Nonmembers $365 Two Days: Members $365 | Nonmembers $465 After December 5 Register at the door: Additional $50 due (space permitting) CREDIT PD/CE/CPE = 2 -------------------------------------------------------------------------------- Register Online Register via Mail/Fax Policies & Procedures Sponsors: Media Partner: -------------------------------------------------------------------------------- CONFERENCE DESCRIPTION 2005 was a relatively strong year for the biotech and specialty pharmaceuticals industry. Global revenues were over $80 billion, compared with $22 billion in 2000. The industry’s market cap closed the year at an all-time high of $488 billion. The IPO market has opened up: Seventeen companies raised $819 million in the U.S. in 2005, with slightly over half currently trading above their IPO price. Small-cap biotech stocks took a downward turn during the first half of 2006, but have been on an incline since August, regaining most of their losses. The Amex Biotechnology Index is up by almost 10% as of early November, and the Nasdaq Biotechnology Index is now flat for the year. Can investors expect a sustained rally before the end of 2006 and into 2007? Don’t miss this chance to learn about the current and future opportunities in specialty pharmaceutical and biotechnology stocks. The CEOs, CFOs, and other VIPs from many of the industry’s most innovative small- and micro-cap companies will discuss their plans to develop and market important new drugs, diagnostics, and delivery technologies. AGENDA Day 1 8:30 Check-in & Continental Breakfast 8:55 Welcome & Opening Remarks 9:00 Outlook for the Biotech & Specialty Pharmaceuticals Industries 9:30 CytRx Corporation (Nasdaq: CYTR) Steven A. Kriegsman, President and CEO Jack Barber, PhD, SVP, Drug Development CytRx, a biopharmaceutical research and development company, is engaged in the development of high-value human therapeutics. 10:10 Break 10:20 DURECT Corporation (Nasdaq: DRRX) Schond L. Greenway, Executive Director, IR & Strategic Planning An emerging specialty pharmaceutical company, DURECT is focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies. 11:00 DRAXIS Health Inc. (Nasdaq: DRAX; TSX: DAX) Martin Barkin, MD, President and CEO DRAXIS Health is a rapidly growing specialty pharmaceutical provider of contract manufacturing services for international clients and radiopharmaceuticals for its own account. 11:40 BioSante Pharmaceuticals, Inc. (AMEX: BPA) Stephen M. Simes, President and CEO BioSante Pharmaceuticals is developing a pipeline of hormone therapy products to treat both men and women. 12:30 Luncheon Presentation: The Emerging Field of Stem Cells Michael D. West, PhD, President and Chief Scientific Officer, Advanced Cell Technology; Author of The Immortal Cell: One Scientist's Quest to Solve the Mystery of Human Aging 1:00 Heska Corporation (Nasdaq: HSKA) Robert Grieve, Chairman and CEO Heska sells advanced veterinary diagnostic and other specialty veterinary products. 1:40 DNAPrint Genomics, Inc. (OTCBB: DNAG) Hector J. Gomez, MD, PhD, Chairman and Chief Medical Officer DNAPrint Genomics offers pharmacogenomics that permit personalized drug development with fewer patients, shorter duration, and lower costs. 2:20 Viral Genetics, Inc. (OTCBB: VRAL) Michael Capizzano, VP, Finance, Business, and Corporate Development A biotech company, Viral Genetics is discovering and developing immune-based therapies for HIV/AIDS and infectious and autoimmune diseases. 3:00 Break 3:10 Xechem International, Inc. (OTCBB: XKEM) Ramesh C. Pandey, PhD, Chairman and CEO Xechem International, a biopharmaceutical company, is engaged in developing drugs for sickle cell disease, malaria, AIDS, and cancer from natural sources. 3:50 Aradigm Corporation (Nasdaq: ARDM) Igor Gonda, PhD, President and CEO Aradigm is using its advanced AERx pulmonary platform and novel formulations to develop novel respiratory products. 4:30 Closing Remarks & Adjournment AGENDA Day 2 8:30 Check-in & Continental Breakfast 8:55 Welcome & Opening Remarks 9:00 Outlook for Small- and Micro-Cap Biotechs Matthew G. Cohen, MD, VP, JP Morgan Investment Management 9:30 Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) Spiro Rombotis, President and CEO Cyclacel Pharmaceuticals is dedicated to the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other disorders. 10:10 Break 10:20 Neuro-Hitech Pharmaceuticals, Inc. (OTCBB: NHPI) Reuben Seltzer, CEO A biopharmaceutical company, Neuro-Hitech Pharmaceuticals is focused on the development and commercialization of next-generation compounds against proven targets for neurodegenerative diseases. 11:00 The Quigley Corporation (Nasdaq: QGLY) Guy Quigley, CEO Albert Piechotta, Director of Communications The Quigley Corporation is a diversified natural health medical science company. 11:40 Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) Craig Dees, PhD, CEO Provectus Pharmaceuticals is a pioneering pharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. 12:20 Lunch 1:00 EntreMed, Inc. (Nasdaq: ENMD) James S. Burns, President and CEO EntreMed, a clinical-stage pharmaceutical company, is developing next-generation multi-mechanism oncology and anti-inflammatory drugs. 1:40 Advanced Cell Technology, Inc. (OTCBB: ACTC) William M. Caldwell, IV, CEO Advanced Cell Technology is a biotechnology company applying human embryonic stem cell technology in the emerging field of regenerative medicine. 2:20 Cleveland BioLabs, Inc. (Nasdaq: CBLI) Michael Fonstein, CEO A drug discovery company, CBLI is developing technology from the Cleveland Clinic that modulates apoptosis. 3:00 Break 3:10 XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB) Ron Bentsur, CEO XTL is focused on the development of novel drugs for infectious disease. 3:50 TBA 4:30 Closing Remarks & Adjournment NYSSA reserves the right to change any part of its published program or list of presenters due to unforeseen circumstances. © NYSSA 2006 privacy | sitemap | press | sponsorship [URL=http://www.nyssa.org/Template.cfm?Section=conferences___seminars&template=/ContentManagement/ContentDisplay.cfm&ContentID=8624]http://www.nyssa.org/Template.cfm?Section=conferences___seminars&template=/Conte ntManagement/ContentDisplay.cfm&ContentID=8624[/URL] [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2